Coronavirus Disease 2019 (COVID-19)

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

New Content ........................................................................................................................................... 3
Public Health Agencies ............................................................................................................................ 3
  Public Health Agency of Canada | canada.ca .......................................................................................... 3
  BC Centre for Disease Control | bccdc.ca .............................................................................................. 3
  Institut national de santé publique .................................................................................................... 3
  CDC: Centers for Disease Control and Prevention | cdc.gov .................................................................. 4
  ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ................................... 4
  FDA: U.S. Food & Drug Administration | fda.gov ........................................................................... 4
  Public Health England | gov.uk ................................................................................................................ 4
  World Health Organization | who.int .................................................................................................. 5
Other relevant government bodies / health care organizations ............................................................. 5
  CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu ........................................ 6
  National Collaborating Centre for Environmental Health | ncceh.ca ......................................................... 6
Updated Daily........................................................................................................................................... 6
COVID-19 resources (case counts) | arcgis.com ...................................................................................... 6
COVID-19 Canada Open Data Working Group | COVID-19 CODWG ..................................................... 6
  Johns Hopkins CCSE | systems.jhu.edu ................................................................................................. 6
NextStrain | nextstrain.org ....................................................................................................................... 6
Guidelines and Technical documents (updated weekly) ...................................................................... 7
Section I: General Guidelines ................................................................................................................ 7
  Ontario / Canada Main Page ................................................................................................................ 7
Reopening/Rebuilding Guidelines .......................................................................................................... 7
Vaccinations - General .......................................................................................................................... 8
Vaccinations - Specific populations .................................................................................................... 12
Vaccinations - Adverse Effects ........................................................................................................... 14
Background Information/Case Definitions ......................................................................................... 16
Laboratories ....................................................................................................................................... 16
Miscellaneous Guidelines .................................................................................................................. 18
Data & Surveillance ............................................................................................................................. 19
Variants – Omicron .............................................................................................................................. 20
Testing ................................................................................................................................................. 21
Symptoms/Treatment ........................................................................................................................... 23
COVID-19 Diagnosis in Children ........................................................................................................ 25
Post-COVID-19 Condition ................................................................................................................... 25
Case Investigation & Contact Tracing ................................................................................................. 26
Infection Prevention and Control ....................................................................................................... 26
Section II: Guidelines for Health Sectors ............................................................................................ 27
Healthcare Providers ............................................................................................................................ 27
Death Services ..................................................................................................................................... 28
Congregate Living (including Long-Term Care, Prisons, and Shelters) ............................................. 28
Section III: Guidelines for the Community ........................................................................................... 30
Travel, Transport & Borders ................................................................................................................ 30
Schools / Childcare .............................................................................................................................. 30
Mental Health /Addiction /Inequity ....................................................................................................... 31
Community .......................................................................................................................................... 32
Businesses/Workplaces ....................................................................................................................... 32
Masks (Non-Medical) .......................................................................................................................... 33
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca
Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- Government of Canada invests $28.2 million in mental health support for trauma and posttraumatic stress disorder [06-27-2022]
  - “Today, on PTSD Awareness Day, the Honourable Carolyn Bennett, Minister of Mental Health and Addictions and Associate Minister of Health, announced an investment of $28.2 million for nine projects to address PTSD and trauma in frontline and essential workers, and others whose mental health has been significantly impacted by the COVID-19 pandemic.”

- Government of Canada invests in supporting those most at risk of posttraumatic stress disorder [06-27-2022]
  - “The new knowledge resulting from these projects will be gathered and shared through a Knowledge Development and Exchange Hub, the Canadian Institutes for Pandemic Health Education and Response (CIPHER), which will help inform mental health interventions addressing PTSD and trauma and enhance Canadian public health policy and practice.”

- Mathematical modelling and COVID-19 [updated regularly]
- COVID-19 daily epidemiology update [updated regularly]
- COVID-19 data trends [updated regularly]

BC Centre for Disease Control | bccdc.ca
- Vaccine standard Operating Procedures:
  - Medicago shipping, storage and use guideline [06-27-2022]
  - Medicago redistribution guidelines [06-27-2022]
- Immunization Manual
  - Summary of changes: admin circular [updated 06-27-2022]
  - COVID-19 vaccine eligibility [updated 06-27-2022]

Institut national de santé publique | inspq.qc.ca
- Infodémie et vaccination contre la COVID-19 au Québec – Aperçu des conversations en ligne de juillet à novembre 2021 [06-27-2022]
- Sous-ignées BA.4 et BA.5 du variant Omicron du SRAS-CoV-2 [06-27-2022]
- Impact des maladies chroniques sur les risques d’hospitalisation et de décès liés à la COVID-19 durant la vague Omicron [06-23-2022]
- Public policy analysis tool for rapid decision making in public health [06-23-2022]
**CDC: Centers for Disease Control and Prevention | cdc.gov**

- Requirement for proof of COVID-19 vaccination for air passengers [06-28-2022]
- COVID-19 hospitalization and death by age [06-27-2022]
- Cases in the U.S. [06-27-2022]
- COVID-19 travel recommendations by country [06-27-2022]
- Archive of COVID-19 vaccination data updates [06-27-2022]
- CDC recommends Moderna COVID-19 vaccine for children and adolescents [06-24-2022]
- COVID-19 vaccine recommendations for children and teens [06-24-2022]
- Stay up to date with your vaccines [06-24-2022]
- COVID-19 vaccine booster shot [06-24-2022]
- COVID-19 vaccines for moderately to severely immunocompromised people [06-24-2022]
- Information about the Moderna COVID-19 vaccine [06-24-2022]
- COVID Data Tracker weekly review [06-24-2022]
- COVID Data Tracker recent updates - 2022-06-23 - a new chart showing COVID-19 vaccination primary series completion, booster dose eligibility, and booster dose receipt by age in the United States was added to the top of the COVID-19 vaccinations in the United States tab. [06-23-2022]

**ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu**

- Country overview report: week 24 2022 [06-23-2022]
- COVID-19 situation update for the EU/EEA, as of 22 June 2022 [06-22-2022]
- COVID-19 situation update worldwide [updated 06-21-2022]
- Data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country [updated regularly]
- Data on COVID-19 vaccination in the EU/EEA [updated regularly]

**FDA: U.S. Food & Drug Administration | fda.gov**

- Coronavirus (COVID-19) update: daily roundup [updated regularly]

**Public Health England | gov.uk**

Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”

- Location of Public Health England (PHE) functions from 1 October 2021
World Health Organization | who.int
- Coronavirus disease (COVID-19) weekly epidemiological update [06-22-2022]
- Log of major changes and errata in WHO daily aggregate case and death count data [updated regularly]
- Draft landscape and tracker of COVID-19 candidate vaccines [updated regularly]
- Coronavirus disease (COVID-19) press briefings [audio posted first; transcripts posted later]
- EPI-WIN: WHO information network for epidemics [updated regularly]
- WHO coronavirus (COVID-19) dashboard [updated regularly]

Other relevant government bodies / health care organizations
- Indigenous Services Canada
  - Coronavirus (COVID-19) and Indigenous communities [updated regularly]
- Statistics Canada
  - COVID-19: a data perspective [updated regularly]
- UK Health Security Agency
  - COVID-19 surveillance and immunity studies [updated 06-28-2022]
  - Investigation of SARS-CoV-2 variants of concern: variant risk assessments [updated 06-24-2022]
  - The R value and growth rate [updated 06-24-2022]
  - COVID-19 variants identified in the UK – latest updates [updated 06-24-2022]
  - Investigation of SARS-CoV-2 variants: technical briefings [updated 06-24-2022]
  - COVID-19 variants: genomically confirmed case numbers [updated 06-24-2022]
  - SARS-CoV-2 variants of public health interest [updated 06-24-2022]
  - COVID-19 test validation approved products [updated 06-24-2022]
  - National flu and COVID-19 surveillance reports published [updated 06-23-2022]
  - PCR home testing for people eligible for COVID-19 treatments [updated 06-22-2022]
- UK Department of Health and Social Care
  - Moderna to open vaccine research and manufacturing centre in UK [06-22-2022]
- UK Department for Education
- UK Department for Transport
  - Travel behaviour, attitudes and social impact of COVID-19 [updated 06-28-2022]
  - Transport use during the coronavirus (COVID-19) pandemic [updated 06-22-2022]
- UK Cabinet Office
  - UK COVID-19 Inquiry: terms of reference [06-28-2022]
- UK Medicines and Healthcare products Regulatory Agency
  - Regulatory approval of COVID-19 Vaccine AstraZeneca [updated 06-27-2022]
  - Coronavirus (COVID-19) vaccines adverse reactions [updated 06-24-2022]
- UK Office for National Statistics
  - Coronavirus (COVID-19) infection survey, UK: 24 June 2022 [06-24-2022]
- Centre for Global Infectious Disease Analysis
CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu
- Rare heart-related side effects higher with Moderna COVID vaccine [06-27-2022]
- COVID-19 Scan for Jun 27, 2022: Down syndrome and COVID-19; Promise for Pfizer Omicron boosters
- COVID-19 vaccines saved an estimated 20 million lives in 1 year [06-24-2022]
- News Scan for Jun 24, 2022: Fourth COVID vaccine dose in elderly; Moderna COVID vaccine for kids; Polio cases in 4 nations
- Kids do get long COVID, but it seems uncommon, data reveal [06-23-2022]
- News Scan for Jun 23, 2022: Maternal COVID vaccine protection; Long COVID in US adults; Flu vaccine in elderly

National Collaborating Centre for Environmental Health | ncceh.ca
- June research scan with COVID-19 sections [06-15-2022]
- May research scan with COVID-19 sections [05-18-2022]
- April research scan with COVID-19 sections [04-20-2022]

ProMED | promedmail.org
- Latest on COVID-19 [individual posts]
- COVID-19 update (146): access to antivirals, reinfection, corr, WHO [06-26-2022]
- COVID-19 update (144): CDC child vacc, N Korea, variants, WHO [06-22-2022]

Updated Daily

COVID-19 resources (case counts) | arcgis.com
- Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
- 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
- Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
- Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
- Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]
Guidelines and Technical documents (updated weekly)

The guidelines listings are current to 06-28-2022; posted 06-28-2022

Section I: General Guidelines

Ontario / Canada Main Page
- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario
- ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
- CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
- CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
- BC B.C.'s response to COVID-19 [updated 06-20-2022]
- AB COVID-19 public health actions [no date]
- SK Living with COVID [no date]
- MB Manitoba Pandemic Response System [no date]
- QC Coronavirus disease (COVID-19) in Québec [06-09-2022]
- NB Living with COVID-19 [no date]
- NL Current Restrictions [no date]
- PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
- NS Reopening plan [updated regularly]
- NW Restrictions and Moving Forward [no date]
- YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
- NT Nunavut’s Path: Living with COVID-19 [no date]
- Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO
- Implementation guidance for assessments of frontline service readiness [07-01-2021]
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]

ECDC
- Data on country response measures to COVID-19 [updated 06-27-2022]
- Transitioning beyond the acute phase of the COVID-19 pandemic: Approaches and tools used by a sample of EU countries in the transition and de-escalation phase – interim report [04-27-2022]
• Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health
• COVID-19 vaccine-relevant information and planning resources [updated 05-02-2022]
• Ethical framework for COVID-19 vaccine distribution [archived] [updated 04-27-2022]

Canada (Federal)
• Adjusting public health measures in the context of COVID-19 vaccination [updated 06-27-2022]
• Health care provider vaccine tool kit, version 3 [06-10-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Initial guidance on a second booster dose of COVID-19 vaccines in Canada [04-05-2022]
• Planning guidance for immunization clinics for COVID-19 vaccines [03-30-2022]
• COVID-19 vaccine guide for youth and adults (12 years and over): Overview [02-02-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
• For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-16-2021]
• COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
• Planning guidance for administration of COVID-19 vaccine [12-21-2020]
• Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
• Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
• Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)
• BC COVID-19 vaccine eligibility [updated 06-24-2022]
• BC Janssen shipping, storage and use guideline [updated 06-15-2022]
• BC COVID-19 vaccine Ad26.COV2.S [recombinant] (Janssen) [updated 06-10-2022]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [updated 06-07-2022]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [updated 06-07-2022]
• BC Spikevax™ (Moderna) [updated 05-13-2022]
• BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 05-13-2022]
• BC Vaxzevria™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 05-13-2022]
• BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) [updated 05-13-2022]
• BC COVID-19 Vaccine ChAdOx1-S [recombinant] [updated 05-13-2022]
• BC Novavax shipping, storage and use guidelines [03-04-2022]
• BC Novavax redistribution guidelines [03-04-2022]
• BC Immunization manual: summary of changes: admin circular [03-04-2022]
• BC COVID-19 vaccine screening checklist [02-25-2022]
• BC Pfizer redistribution guidelines [02-08-2022]
• BC Point of care risk assessment (PCRA) [no date]
• BC Janssen redistribution guidelines [01-17-2022]
• BC Regulated and unregulated health professionals SARS-CoV-2 immunization order [01-09-2022]
• BC Emergency medical assistants SARS-CoV-2 immunization order [updated 01-09-2022]
• BC Moderna redistribution guidelines [01-06-2022]
• BC Administrative circular [12-31-2021]
• BC 2021/22 seasonal influenza vaccine eligibility [10-00-2021]
• BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [10-15-2021]
• BC Latex content in vaccines [10-00-2021]
• BC Immunization manual appendix A: informed consent (page 4) [updated 09-00-2021]
• BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [08-31-2021]
• BC COVID-19 vaccination: why your 2nd dose is important [08-27-2021]
• BC Vaccine SOP: cold chain incident reporting process [updated 07-21-2021]
• BC Pfizer vaccine sub dose vial reporting [07-13-2021]
• BC COVID-19 Pfizer vaccine partial tray ULT distribution guidelines [05-19-2021]
• BC Cold chain assets warranty contact information [05-05-2021]
• BC Vaccine SOP: return of materials to manufacturers [04-30-2021]

WHO
• Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [06-06-2022]
• Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [06-06-2022]
• COVID-19 and mandatory vaccination: ethical considerations and caveats [05-30-2022]
• COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.3 [updated 04-21-2022]
• Injection safety in the context of coronavirus disease (COVID-19) vaccination: addendum to policy brief, 5 April 2022 [04-05-2022]
• Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19v [03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [updated 03-15-2022]
• Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [03-15-2022]
• Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: grading of evidence – evidence to recommendations tables [03-15-2022]
• Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience) [03-15-2022]
• Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [03-15-2022]
• Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [03-15-2022]
• Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
• NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
• Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [01-21-2022]
• COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
• Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
• Injection safety in the context of coronavirus disease (COVID-19) vaccination [11-05-2021]
• Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
• Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• Training on handling, storing and transporting Pfizer BioNTech COVID-19 vaccine COMIRNATY® (Tozinameran) [08-04-2021]
• Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
• Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
• Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief [05-26-2021]
• Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
• AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
• AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine [05-10-2021]
• Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
• COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
• Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
• Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
• Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
• COVID-19 vaccine boosters [updated 06-24-2022]
• Stay up to date with your COVID-19 vaccines [updated 06-14-2022]
• COVID-19 vaccine reporting systems [updated 06-19-2022]
• Understanding viral vector COVID-19 vaccines [updated 06-16-2022]
• COVID-19 vaccination clinical & professional resources [updated 05-13-2022]
• Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 02-02-2022]
• Communication resources for COVID-19 vaccines [12-11-2021]
• COVID-19 vaccination program operational guidance [10-14-2021]
• Public health investigations of COVID-19 vaccine breakthrough cases: case investigations protocol [no date]
• Interim guidance for routine and influenza immunization services during the COVID-19 pandemic [04-15-2021]
• Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]

UK
• COVID-19 vaccination programme [updated 05-20-2022]
• Monitoring reports of the effectiveness of COVID-19 vaccination [updated 04-28-2022]
• National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [updated 04-01-2022]
• National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine [updated 04-01-2022]
• National protocol for Spikevax (formerly COVID-19 vaccine Moderna) [updated 04-01-2022]
• COVID-19 vaccination: information for healthcare practitioners [updated 03-10-2022]
• COVID-19: the green book, chapter 14a [updated 02-28-2022]
• COVID-19 vaccination: vaccine product information [02-23-2022]
• COVID-19 vaccination: blood clotting information for healthcare professionals [updated 02-14-2022]
• COVID-19 vaccination: booster dose resources [updated 02-02-2022]
• National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [11-20-2021]
• COVID-19 vaccination: what to expect after vaccination [updated 11-09-2021]
• Monitoring of the effectiveness of COVID-19 vaccination [09-14-2021]
• COVID-19: vaccine surveillance strategy [03-29-2021]

ECDC
• Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose [04-28-2022]
• Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA [updated 04-21-2022]
• Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update [03-14-2022]
• Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA [12-14-2021]
• Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA [10-15-2021]
• Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update [03-14-2022]
• Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0 [10-08-2021]
• Interim public health considerations for the provision of additional COVID-19 vaccine doses [09-01-2021]
• Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence [07-22-2021]
• Countering online vaccine misinformation in the EU/EEA [06-29-2021]

Australia
• ATAGI recommendations on the use of a booster dose of COVID-19 vaccine [updated 06/27/2022]
• COVID-19 vaccination – information on COVID-19 Pfizer (COMIRNATY) vaccine [updated 06-17-2022]
• Clinical recommendations for COVID-19 vaccines [updated 06/17/2022]
• COVID-19 vaccination – vaccine dose policy [updated 05-27-2022]
• ATAGI clinical guidance for COVID-19 vaccine providers [02/23/2022]
• COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination 02-22-2022]
• COVID-19 vaccination – updated provider kit for general practices [12-14-2021]

Vaccinations - Specific populations

Canada (Federal)
• NACI rapid response: guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age [modified 03-24-2022]
• NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age [archived] [modified 03-17-2022]
• COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [modified 03-11-2022]
• NACI rapid response: updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [modified 02-09-2022]
Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview [modified 02-03-2022]

Planning for the 2021-2022 school year in the context of COVID-19 vaccination [modified 02-02-2022]

Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [updated 01-25-2022]

NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Provinces and territories (other than Ontario)

BC Health professionals COVID-19 vaccination status information and preventive measures – June 10, 2022 [updated 06-10-2022]

BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent [updated 05-13-2022]

BC COVID-19 vaccination for children age 5-11 frequently asked questions for community practitioners [03-07-2022]

BC Residential care COVID–19 vaccination status [02-28-2022]

WHO

Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-25-2021]

Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]

Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC

Resources to promote the COVID-19 vaccine for children & teens [updated 06-19-2022]

COVID-19 vaccines for children and teens [updated 06-19-2022]

COVID-19 vaccine information for specific groups [updated 06-19-2022]

COVID-19 vaccines while pregnant or breastfeeding [updated 06-13-2022]

COVID-19 vaccines for people who would like to have a baby [updated 04-14-2022]

COVID-19 vaccine equity for racial and ethnic minority groups [updated 03-29-2022]

Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [updated 01-20-2022]

Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]

Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [4-30-2021]
• COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [updated 04-11-2022]
• COVID-19 vaccination: resources for children aged 5 to 11 years [updated 03-28-2022]
• COVID-19 vaccination: resources for children and young people aged 12 to 17 years [updated 02-01-2022]
• COVID-19 vaccination: guide for adults [updated 01-19-2022]
• Interim public health considerations for COVID-19 vaccination of children aged 5-11 years [12-01-2021]
• Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

ECDC
• Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1 [02-18-2022]
• COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose [02-08-2022]
• Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA [06-01-2021]

Australia
• ATAGI – provider guide to COVID-19 vaccination of people with immunocompromise [updated 06-17-2022]
• ATAGI – COVID-19 vaccination – shared decision making guide for people with immunocompromise [updated 06-17-2022]
• COVID-19 vaccination – shared decision making guide for people receiving palliative care or end-of-life care [updated 06-17-2022]
• COVID-19 vaccination – COVID-19 vaccination decision guide for women who are pregnant, breastfeeding or planning pregnancy [updated 06-17-2022]
• COVID-19 vaccination – vaccine dose policy [updated 05-27-2022]
• ATAGI expanded guidance on temporary medical exemptions for COVID-19 vaccines [updated 04-29-2022]
• Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose [04-28-2022]
• COVID-19 vaccination – COVID-19 vaccine information for the residential aged care workforce [03-29-2022]
• COVID-19 vaccination – COVID-19 vaccination decision guide for frail older people, including those in residential aged care facilities [updated 03-28-2022]
older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

- Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)

- BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
- BC Guidance document on the management of inadvertent vaccine errors [02-04-2022]
- BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
- BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]

CDC

- Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination [02-11-2022]
- Possible side effects after getting a COVID-19 vaccine [01-12-2022]
- Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [reviewed 08-09-2021]

WHO

- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- How to monitor and report COVID-19 vaccine side effects [03-15-2021]

UK

- Coronavirus (COVID-19) vaccine adverse reactions [updated 06-24-2022]
- COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [updated 03-21-2022]
- Myocarditis and pericarditis after COVID-19 vaccination [updated 03-21-2022]
- COVID-19 vaccination: Guillain-Barré Syndrome information for healthcare professionals [updated 12-17-2021]
- Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

Australia

- ATAGI clinical guidance on COVID-19 vaccine administration errors [updated 04-08-2022]
- COVID-19 vaccination – guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [04-28-2022]
- COVID-19 vaccination – primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine [updated 03-01-2022]

Back to Top
Background Information/Case Definitions

Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [01-17-2022]

PHAC
- National case definition: coronavirus disease (COVID-19) [updated 06-07-2022]
- COVID-19 case report form [01-11-2021]

CDC
- Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [updated 12-23-2021]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 14.2) [updated 06-02-2022]

PHAC
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [updated 04-12-2022]
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [11-23-2021]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

WHO
- Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19 [updated 03-24-2022]
- **Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2** [03-30-2021]
- **Laboratory biosafety guidance related to coronavirus disease (COVID-19)** [01-28-2021]
- **COVID-19 new variants: knowledge gaps and research** [01-12-2021]
- **Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health** [01-08-2021]
- **SARS-CoV-2 genomic sequencing for public health goals** [01-08-2021]
- **SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide** [12-21-2020]
- **Assessment tool for laboratories implementing SARS-CoV-2 testing** [10-23-2020]
- **Diagnostic testing for SARS-CoV-2: interim guidance** [09-11-2020]
- **Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays** [09-11-2020]

**CDC**

- **Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19** [05-18-2022]
- **Testing strategies for SARS-CoV-2** [updated 05-05-2022]
- **How to report COVID-19 laboratory data** [updated 04-04-2022]
- **Guidance for SARS-CoV-2 point-of-care and rapid testing** [updated 04-04-2022]
- **Guidance for reporting SARS-CoV-2 sequencing results** [03-21-2022]
- **Evaluation for SARS-CoV-2 testing in animals** [updated 03-30-2022]
- **Guidance for general laboratory safety practices during the COVID-19 pandemic** [updated 03-02-2022]
- **Using antibody tests for COVID-19** [updated 02-24-2022]
- **Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings** [updated 01-24-2022]
- **Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19)** [12-13-2021]
- **Frequently asked questions on COVID-19 testing for laboratories** [11-12-2021]
- **Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity** [10-29-2021]
- **Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination** [08-09-2021]
- **Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing** [06-30-2021]
- **Variants and genomic surveillance for SARS-CoV-2** [04-02-2021]
- **Resources for laboratories working on coronavirus (COVID-19)** [03-28-2021]
- **Information for laboratories about coronavirus (COVID-19)** [03-28-2021]

**UK**

- **Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [updated 06-06-2022]
• National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests [updated 06-06-2022]
• Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [updated 06-06-2022]
• Technical validation protocol for SARS-CoV-2 nucleic acid detection [updated 06-06-2022]
• NHS test and trace statistics (England): methodology [updated 05-18-2022]
• How tests and testing kits for coronavirus (COVID-19) work [updated 02-14-2022]
• COVID-19: guidance for sampling and for diagnostic laboratories [03-29-2021]

ECDC
• The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates [05-10-2021]

Australia
• PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Miscellaneous Guidelines

PHAC
• Individual public health measures [updated 06-24-2022]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [updated 04-08-2022]
• COVID-19 and people with disabilities in Canada [updated 04-04-2022]
• Individual and community-based measures to mitigate the spread of COVID-19 in Canada [02-02-2022]

Canadian provinces and territories (other than Ontario)
• BC COVID-19 ethical decision-making framework [12-24-2020]

WHO
• Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
• Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
• ACT-Accelerator 'fair share asks' - by country [02-09-2022]
• WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
• Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
• Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
• Critical preparedness, readiness and response actions for COVID-19: interim guidance [05-27-2021]

CDC
• **Public health guidance for potential COVID-19 exposure associated with travel** [updated 06-13-2022]
• **Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals** [reviewed 01-31-2022]
• **Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance)** [updated 01-21-2022]
• **RRT composition: COVID-19 considerations** [03-01-2021]
• **Managing investigations during an outbreak** [07-31-2020]
• **Optimizing supply of PPE and other equipment during shortages** [07-16-2020]

**ECDC**
• **Conducting in-action and after-action reviews of the public health response to COVID-19** [06-03-2022]
• **One-day in-action review (IAR) protocol in the context of COVID-19** [03-00-2021]
• **Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA** [02-17-2021]

**Australia**
• **CDNA National guidelines for public health units** [updated 06-03-2022]

**Other**
• **Public health ethics and COVID-19: selected resources** – National Collaborating Centre for Healthy Public Policy [11-30-2021]

**Data & Surveillance**

**Canada**
• **COVID-19 data trends** [modified 06-24-2022]
• **Mathematical modelling and COVID-19** [modified 04-01-2022]
• **National surveillance guidelines for coronavirus disease (COVID-19)** [03-19-2021]

**WHO**
• **Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance** [04-14-2022]
• **Public health surveillance for COVID-19: interim guidance** [updated 02-14-2022]
• **End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance** [01-31-2022]
• **Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States** [01-21-2022]

**CDC**
- Wastewater surveillance data reporting & analytics [updated 04-08-2022]
- National wastewater surveillance system (NWSS) [updated 03-21-2022]
- Wastewater surveillance testing methods [01-26-2022]
- Public health interpretation and use of wastewater surveillance data [01-26-2022]
- Developing a wastewater surveillance sampling strategy [01-26-2022]
- Targeted wastewater surveillance at facilities, institutions, and workplaces [01-26-2022]
- COVID-19 serology surveillance [03-11-2021]
- Data visualization [02-16-2021]
- Large-scale geographic seroprevalence surveys [10-02-2020]

ECDC
- Organisation of vector surveillance and control in Europe [12-13-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30) [11-29-2021]
- COVID-19 variants: genically confirmed case numbers [updated 11-29-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
- COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
- Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]

UK
- COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]

Variants – Omicron

Canada
- SARS-CoV-2 variants: national definitions, classifications and public health actions [03-09-2022]

CDC
- Omicron variant: what you need to know [updated 03-29-2022]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [updated 06-24-2022]
- SARS-CoV-2 variants of public health interest [updated 06-24-2022]

ECDC
- Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA [06-13-2022]
- Technical guidance for antigenic SARS-CoV-2 monitoring [updated 06-07-2022]
- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update [updated 01-27-2022]
- Methods for the detection and characterisation of SARS-CoV-2 variants – first update [12-20-2021]
- Threat assessment brief: implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern (Omicron) fo the EU/EEA first update [12-02-2021]
• Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
• Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]

WHO
• Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states [updated 01-21-2022]

Testing
Canada
• Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [updated 09-08-2021]
• Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [02-23-2021]
• Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
• National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

Ontario Ministry of Health
• Management of cases and contacts of COVID-19 in Ontario. Version 14 [amended 06-02-2022]
• COVID-19 provincial testing guidance. Version 15.0 [04-11-2022]
• COVID-19 test requisition [06-12-2021]
• Considerations for privately-initiated testing. version 3.0 [05-21-2021]
• COVID-19 guidance: considerations for rapid antigen screening. Version 2.0 [02-17-2021]
• Considerations for employer rapid antigen screening pilot [11-20-2020]

Canadian provinces and territories (other than Ontario)
• BC COVID-19: viral testing guidelines for British Columbia [updated 03-23-2022]
• BC COVID-19 infection prevention and control: guidance for test collection & assessment centres [09-09-2021]
• BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
• BC Antibody testing (serology) page [no date]

WHO
• Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

CDC
• Testing strategies for SARS-CoV-2 [updated 05-05-2022]
• Guidance on prevention and management of coronavirus disease 2019 (COVID-19) in correctional and detention facilities [updated 05-03-2022]
• Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community [updated 04-04-2022]
• Guidance for SARS-CoV-2 point-of-care and rapid testing [updated 04-04-2022]
• Using antibody tests for COVID-19 [updated 02-24-2022]
• SARS-CoV-2 antigen testing in long term care facilities [updated 02-17-2022]
• **Overview of testing for SARS-CoV-2 (COVID-19)** [updated 02-11-2022]
• **Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic** [updated 02-02-2022]
• **Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes: nursing homes & long-term care facilities** [updated 02-02-2022]
• **CDC’s diagnostic test for COVID-19 only and supplies** [10-05-2021]
• **Guidance for health departments about COVID-19 testing in the community** [08-30-2021]
• **CDC diagnostic tests for covid-19** [08-07-2021]
• **Nucleic acid amplification tests (NAATs)** [06-14-2021]
• **Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing** [06-14-2021]
• **Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings** [03-29-2021]
• **Serology testing for COVID-19 at CDC** [11-03-2020]

**UK**

• **Investigation of SARS-CoV-2 variants: technical briefings** [updated 06-24-2022]
• **SARS-CoV-2 variants of public health interest** [updated 06-24-2022]
• **Investigation of SARS-CoV-2 variants of concern: variant risk assessments** [updated 06-24-2022]
• **SARS-CoV-2 variant of concern diagnostic assurance** [updated 04-14-2022]
• **Testing for coronavirus (COVID-19) before hospital** [updated 03-08-2022]
• **Coronavirus COVID-19 serology and viral detection tests: technical validation reports** [updated 02-18-2022]
• **How tests and testing kits for coronavirus (COVID-19) work** [updated 02-14-2022]
• **Investigation of SARS-CoV-2 variants of concern: technical briefings** [09-17-2021]
• **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021** [07-16-2021]
• **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021** [07-16-2021]
• **SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence** [10-16-2020]

**ECDC**

• **A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control** [04-27-2022]
• **Assessment of point-of-care testing devices for infectious disease surveillance, prevention and control – a mapping exercise** [04-27-2022]
• **Considerations for the use of antibody tests for SARS-CoV-2 – first update** [02-10-2022]
• **Methods for the detection and identification of SARS-CoV-2 variants- first update** [12-20-2021]
• **Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories** [12-20-2021]
• **Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK** [10-26-2021]
• **Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings** [05-06-2021]
• Considerations for the use of saliva as sample material for COVID-19 testing [05-03-2021]
• Considerations on the use of self-tests for COVID-19 in the EU/EEA [03-17-2021]
• Guidance for COVID-19 quarantine and testing of travellers [03-12-2021]
• Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA [02-16-2021]
• Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update [02-15-2021]
• COVID-19 testing strategies and objectives [09-18-2020]
• Objectives for COVID-19 testing in school settings [08-10-2020]

Australia
• PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [updated 02-20-2022]
• PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Symptoms/Treatment

Canada
• Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply [modified 06-17-2022]
• COVID-19 signs, symptoms and severity of disease: a clinician guide [modified 06-01-2022]
• COVID-19 for health professionals: treatments [modified 02-01-2022]
• Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health
• Management of cases and and contacts of COVID-19 in Ontario version 14.2 [updated 06-02-2022]
• COVID-19 patient screening guidance document version 5.0 [08-26-2021]

WHO
• Living guidance for clinical management of COVID-19 [11-23-2021]
• COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
• Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
• WHO living guideline: drugs to prevent COVID-19 [03-02-2021]
• Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC
• Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 06-15-2022]
• Clinical considerations for care of children and adults with confirmed COVID-19 [05-27-2022]
• Clinical care guidance for healthcare professionals about coronavirus (COVID-19) [04-29-2022]
• Caring for post-COVID conditions [updated 03-21-2022]
• Clinical care quick reference for COVID-19 [updated 03-16-2022]
• Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [updated 02-25-2022]
• Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 [updated 02-15-2022]
• If you are sick or caring for someone [02-09-2022]
• Ending home isolation for persons with COVID-19 not in healthcare settings [updated 01-14-2022]
• Ending isolation and precautions for people with COVID-19: interim guidance [updated 01-14-2022]
• Standard operating procedure (SOP) for triage of suspected COVID-19 patients in non-US healthcare settings: early identification and prevention of transmission during triage [10-18-2021]
• Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
• Assessing risk factors for severe COVID-19 illness [11-30-2020]

WHO
• Therapeutics and COVID-19 [updated 04-22-2022]
• COVID-19 clinical care pathway (CARE): confirm, assess, respond, evaluate [02-04-2022]
• COVID-19 clinical care pathway (CARE): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery [02-04-2022]
• COVID-19 clinical management: living guidance [11-23-2021]
• Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [07-15-2021]
• Hypertension and COVID-19 [06-17-2021]
• WHO information note: COVID-19 considerations for tuberculosis (TB) care [05-05-2021]
• Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]
• WHO COVID-19 clinical care bundle [04-23-2021]
• Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance [08-13-2020]

US NIH
• COVID-19 treatment guidelines [updated 05-31-2022]

UK
• COVID-19: migrant health guide [updated 03-08-2022]
• COVID-19: long-term health effects [04-30-2021]

Australia
• Coronavirus (COVID-19) – identifying the symptoms [last updated 11-11-2020]
COVID-19 Diagnosis in Children
Canada
- COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children (MIS-C) [12-09-2021]

WHO

CDC
- Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [05-20-2021]

Other
- BC Children with immune compromise [11-30-2021]
- BC Pediatric clinical guidance for COVID-19 [09-27-2021]
- BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]
- BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]

Post-COVID-19 Condition
Canada
- Post COVID-19 condition [updated 06-27-2021]

Ontario
- BC Living with persistent Post-COVID-19 symptoms
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

CDC
- Post-COVID conditions; CDC Science [06-17-2022]
- Caring for post-COVID conditions [03-21-2022]
- Post-COVID conditions: information for healthcare providers [07-09-2021]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

UK
- Long-term effects of coronavirus (long COVID) [05-25-2022]
Case Investigation & Contact Tracing

Canada
- Public health management of cases and contacts associated with COVID-19 [updated 06-10-2022]

Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 14.2) [updated 06-02-2022]

WHO
- Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [02-17-2022]

CDC
- Quarantine and isolation [03-30-2022]
- Contact tracing resources for health departments [03-25-2022]
- Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [02-28-2022]
- Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-28-2022]
- Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-28-2022]
- Contact tracing for COVID-19 [02-10-2022]
- Investigating a COVID-19 case [01-21-2022]
- Ending home isolation for persons with COVID-19 not in healthcare settings [01-14-2022]
- COVID-19 contact tracing communications toolkit for health departments [11-05-2021]
- Global contact tracing [01-15-2021]

UK
- People with symptoms of a respiratory infection including COVID-19 [06-10-2022]

Infection Prevention and Control

PHAC / Health Canada
- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]
- Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [01-07-2022]
- Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed– December 23, 2021 [12-24-2021]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

Ontario
- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)
- BC COVID-19: outbreak management protocol for acute care settings [02-02-2022]

WHO
- WHO COVID-19 infection prevention and control (IPC) pillar achievements, February 2020 – January 2021 [05-14-2021]
- Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]

CDC
- Considerations for inpatient obstetric healthcare settings [11-19-2021]
- Cleaning and disinfecting your facility: every day and when someone is sick [11-15-2021]

UK
- Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [05-26-2022]
- Technical specifications for personal protective equipment (PPE) [02-14-2022]

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health
- COVID-19 guidance: acute care v.8 [updated 06-11-2022]
- COVID-19 Guidance: Personal Protective Equipment (PPE) for Health Care Workers and Health Care Entities version 1.0 [06-10-2022]

Canada
- COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

WHO
- COVID-19 home care bundle for health care workers [02-09-2022]

Back to Top
- Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
- Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
- CDC
  - Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [01-21-2022]
  - Staff shortages [01-21-2022]
  - Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings [01-14-2022]
- UK
  - COVID-19: managing healthcare staff with symptoms of a respiratory infection [04-01-2022]
- Death Services
  - Ontario
    - ON Bereavement Authority of Ontario COVID-19 [03-17-2022]
  - WHO
    - Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance [09-04-2020]
  - CDC
    - Collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19: interim guidance [04-04-2022]
    - Recommendations to reduce the spread of COVID-19 in Tribal settings [04-15-2022]
  - UK
    - Handling the deceased with suspected or confirmed COVID-19 [04-01-2022]
  - Other
    - QC COVID-19: preventive and protective measures for funeral services businesses [07-30-2021]
- Congregate Living (including Long-Term Care, Prisons, and Shelters)
  - Ontario Ministry of Health
COVID-19: guidance on pets and long-term care homes [07-20-2021]
Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO
Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC
Correctional and detention facilities [06-10-2022]
Guidance on prevention and management of COVID-19 in correctional and detention facilities [05-03-2022]
Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments [04-06-2022]
How to protect yourself and others [02-25-2022]
Investigating cases in homeless shelters [02-10-2022]
Interim guidance on people experiencing unsheltered homelessness [02-10-2022]
Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [02-10-2022]
Infection control for nursing homes [02-02-2022]
Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]
Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [04-30-2021]
Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]

UK
Infection prevention and control in adult social care: COVID-19 supplement [05-03-2022]
Flu and acute respiratory illness in prisons and secure settings: information for staff [04-06-2022]
COVID-19: guidance for hostel services for people experiencing homelessness and rough sleeping [04-04-2022]
Visiting someone in prison [04-01-2022]
Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [03-21-2022]
COVID-19: provision of night shelters [03-10-2022]
Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1 [02-18-2022]
Infection control in prisons and places of detention [07-01-2011]

Other
Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health
- Travelling during COVID-19 [06-17-2022]
- Guidance for public transit agencies and passengers in response to COVID-19 [03-21-2022]

Canada
- Official global travel advisories [updated often]
- Provincial and territorial restrictions [06-20-2022]
- COVID-19: travel, testing, quarantine and borders [05-27-2022]

CDC
- COVID-19 travel recommendations by destination [updated regularly]
- Stay up to date with your COVID-19 vaccines [updated 06-24-2022]
- Requirement for proof of COVID-19 vaccination for air passengers [06-13-2022]
- Non-U.S. citizen, Non-U.S. immigrants: air travel to the United States [06-13-2022]
- Requirement for proof of negative COVID-19 test or recovery from COVID-19 for all air passengers arriving in the United States [06-13-2022]
- Required testing before air travel to the US [06-13-2022]

UK
- People with symptoms of a respiratory infection including COVID-19 [06-10-2022]
- Coronavirus (COVID-19): advice for heavy goods (HGV) and public service vehicle (PSV) operators [03-29-2022]
- Coronavirus (COVID-19): cruise ship travel [03-17-2022]

Other
- Emergency response plan and action checklist for use by air carriers in the event of a public health emergency [no date]

Schools / Childcare

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario version 14.2 [06-02-2022]
- COVID-19: health and safety measures at schools [03-31-2022]
- COVID-19: health and safety measures for child care [03-31-2022]

PHAC
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [02-02-2022]
- Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [01-07-2022]
Coronavirus Disease 2019 (COVID-19): 06/28/2022

**CDC**
- [Guidance for K-12 schools and childcare programs](#) [05-27-2022]
- [Schools, child care, and colleges](#) [05-27-2022]
- [Considerations for institutions of higher education](#) [02-07-2022]

**UK**
- [Emergency planning and response for education, childcare, and children's social care settings](#) [06-07-2022]

---

**Mental Health /Addiction /Inequity**

**Ontario Ministry of Health**
- [COVID-19 guidance: mental health and addictions service providers in community settings: version 2](#) [09-24-2020]

**PHAC**
- [Helping people who use substances during the COVID-19 pandemic](#) [07-06-2021]

**Provinces & Territories (excluding Ontario)**
- QC [Preventing loneliness in young adults in the context of a pandemic](#) [04-05-2022]
- QC [Public health ethics and COVID-19: selected resources](#) [11-00-2021]
- BC [COVID-19: provincial episodic overdose prevention service (e-OPS) protocol](#) [06-26-2020]

**WHO**
- [Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022](#) [03-02-2022]
- [Rise, respond, recover: renewing progress on women's, children's and adolescent's health in the era of COVID-19](#) [12-00-2021]
- [Social isolation and loneliness among older people: advocacy brief](#) [07-29-2021]
- [Smoking and COVID-19](#) [06-30-2020]
- [Addressing violence against children, women and older people during the COVID-19 pandemic: key actions](#) [06-18-2020]
- [COVID-19 and violence against women: what the health sector / system can do](#) [04-07-2020]

**CDC / SAMHSA**
- [Disaster planning handbook for behavioural health service programs](#) [03-00-2021]
- [Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020](#) [05-07-2020]
Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020 [03-19-2020]

Intimate partner violence and child abuse considerations during COVID-19 [no date]

UK

Alcohol and drug misuse prevention and treatment guidance [03-07-2022]

Every Mind Matters: looking after your mental health [no date]

Domestic abuse: how to get help [11-11-2021]

Community

Ontario Ministry of Health

COVID-19 public health measures and advice [no date]

Guidance on community emergency evacuations: version 2 [05-16-2022]

PHAC

COVID-19 and people with disabilities in Canada [04-04-2022]

Reducing COVID-19 risk in community settings: a tool for operators [02-10-2022]

Individual and community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada [02-02-2022]

Accessing additional public health support for First Nations and Inuit communities during COVID-19 [01-28-2022]

At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

WHO

WHO mass gathering COVID-19 risk assessment tool: generic events, version 3 [06-16-2022]

CDC


Considerations for owners and operators of multifamily housing including populations at increased risk for complications from COVID-19 [05-05-2021]

Information about COVID-19, pets, and other animals [04-14-2022]

Operational considerations for community isolation centers [03-30-2022]

Breastfeeding & caring for newborns [01-20-2022]

Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-04-2021]

UK

Living safely with respiratory infections, including COVID-19 [06-16-2022]

Infection prevention and control in adult social care: COVID-19 supplement [05-03-2022]

COVID-19: guidance for providers of accommodation for asylum seekers [04-04-2022]
• COVID-19 public health measures and advice [no date]
• COVID-19 worker and employee screening [06-11-2022]
• Outbreak guidance: workplace and living settings for Seasonal International Agriculture Workers (IAWs) [04-14-2022]
• COVID-19 and workplace health and safety [03-28-2022]
• Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization [11-30-2021]

WHO
• Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
• Workplaces & businesses: plan, prepare and respond [10-18-2021]
• Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

UK
• Reducing the spread of respiratory infections, including COVID-19, in the workplace [updated 06-10-2022]

Masks (Non-Medical)
Ontario Ministry of Health
• Face coverings and face masks [06-11-2022]

PHAC
• COVID-19 mask use: advice for community settings [04-22-2022]

WHO
• What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? [00-00-2021]
• Mask use in the context of COVID-19 [12-01-2020]

CDC
• Your guide to masks [02-25-2022]

ECDC
• Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern [02-07-2022]

UK
• Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [updated 06-16-2022]
• The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]